Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Hepion Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEXT-GENERATION, NON-INVASIVE DIAGNOSTIC PLATFORM HAS POTENTIAL APPLICATIONS IN SOLID TUMOR TYPES BEYOND LIVER CANCER LICENSING DEAL REFLECTS HEPION'S STRATEGIC SHIFT TO ADVANCING CLINICALLY PROVEN LIQUID BIOPSY TESTS UNDER NEW LEADERSHIP MORRISTOWN, N.J., MARCH 03, 2026 (GLOBE NEWSWIRE) -- HEPION PHARMACEUTICALS, INC. (OTCQB:HEPA), A PRECISION DIAGNOSTICS COMPANY, TODAY ANNOUNCED THAT IT HAS IN-LICENSED FROM CIRNA DIAGNOSTICS LLC, A NOVEL BIOMARKER ASSAY THAT DETECTS MUTANT CIRCULATING TUMOR RNA (CTRNA) TO FACILITATE EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA (HCC) IN HIGH-RISK PATIENTS (CIRRHOSIS).

HEPION PHARMACEUTICALS IN-LICENSES CTRNA BIOMARKER ASSAY TO FACILITATE EARLY DIAGNOSIS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA

MORRISTOWN, N.J., JUNE 25, 2025 (GLOBE NEWSWIRE) -- HEPION PHARMACEUTICALS, INC. (OTCQB:HEPA), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY THAT IS DEVELOPING AND COMMERCIALIZING DIAGNOSTIC TESTS FOR CELIAC DISEASE, RESPIRATORY MULTIPLEX (COVID/INFLUENZA A/B AND RSV), HELICOBACTER PYLORI (H.

HEPION PHARMACEUTICALS SUCCESSFULLY COMPLETES APPLICATION TO THE OTCQB

MORRISTOWN, N.J., MAY 12, 2025 (GLOBE NEWSWIRE) -- HEPION PHARMACEUTICALS, INC. (NASDAQ:HEPA), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY THAT HAD BEEN DEVELOPING A TREATMENT FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH), HEPATOCELLULAR CARCINOMA (HCC), AND OTHER CHRONIC LIVER DISEASES WHICH HAS TRANSITIONED TO A DEVELOPER AND DISTRIBUTOR OF DIAGNOSTIC TESTS FOR CELIAC DISEASE, RESPIRATORY MULTIPLEX (COVID/INFLUENZA A/B AND RSV), H. PYLORI AND HCC, TODAY ANNOUNCED THAT ON MAY 9, 2025, THE COMPANY RECEIVED WRITTEN NOTICE (THE NOTICE) FROM THE OFFICE OF GENERAL COUNSEL OF THE NASDAQ STOCK MARKET (NASDAQ) INDICATING THAT THE NASDAQ HEARINGS PANEL HAS DETERMINED TO DELIST THE COMPANY'S SHARES FROM NASDAQ DUE TO THE COMPANY'S FAILURE TO MEET NASDAQ'S CONTINUED LISTING STANDARDS. AS PREVIOUSLY DISCLOSED, THE COMPANY HAS NOT BEEN COMPLIANT WITH THE REQUIREMENTS UNDER NASDAQ LISTING RULE 5550(A)(2) TO MAINTAIN A MINIMUM BID PRICE OF $1.00 PER SHARE AND NASDAQ LISTING RULE 5101 INDICATING THAT NASDAQ BELIEVES THE COMPANY IS A PUBLIC SHELL. THE NOTICE INDICATED THAT TRADING IN THE COMPANY'S SHARES OF COMMON STOCK (THE COMMON STOCK) ON NASDAQ WILL BE SUSPENDED EFFECTIVE AT THE OPEN OF TRADING ON TUESDAY, MAY 13, 2025.

HEPION PHARMACEUTICALS ANNOUNCES RECEIPT OF DELISTING NOTIFICATION FROM NASDAQ

MORRISTOWN, N.J., MAY 07, 2025 (GLOBE NEWSWIRE) -- HEPION PHARMACEUTICALS, INC. (NASDAQ:HEPA), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY THAT HAD BEEN DEVELOPING A TREATMENT FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH), HEPATOCELLULAR CARCINOMA (HCC), AND OTHER CHRONIC LIVER DISEASES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A BINDING LETTER OF INTENT (LOI) WITH NEW DAY DIAGNOSTICS LLC TO IN-LICENSE DIAGNOSTIC TESTS FOR CELIAC DISEASE, RESPIRATORY MULTIPLEX (COVID/INFLUENZA A/B AND RSV), HELICOBACTER PYLORI (H. PYLORI) AND HEPATOCELLULAR CARCINOMA (HCC). THE CELIAC, RESPIRATORY MULTIPLEX AND H. PYLORI TESTS HAVE CE MARKS AND ARE ELIGIBLE TO BE SOLD IN EUROPE AT THE PRESENT TIME.

HEPION PHARMACEUTICALS EXECUTES BINDING LETTER OF INTENT WITH NEW DAY DIAGNOSTICS TO COMMERCIALIZE DIAGNOSTIC TESTS FOR CELIAC DISEASE, RESPIRATORY MULTIPLEX, H. PYLORI AND HCC

SHARES EXPECTED TO BEGIN TRADING ON SPLIT-ADJUSTED BASIS ON MARCH 18, 2025 MORRISTOWN, N.J., MARCH 14, 2025 (GLOBE NEWSWIRE) -- HEPION PHARMACEUTICALS, INC. (NASDAQ: HEPA), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY THAT HAS BEEN DEVELOPING A TREATMENT FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH), HEPATOCELLULAR CARCINOMA (HCC), AND OTHER CHRONIC LIVER DISEASES, TODAY ANNOUNCED THAT IT WILL IMPLEMENT A 1-FOR-50 REVERSE SPLIT OF THE ISSUED SHARES OF ITS COMMON STOCK, EFFECTIVE AT 4:01 P.M.

HEPION PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT

EDISON, N.J., DEC. 11, 2024 (GLOBE NEWSWIRE) -- HEPION PHARMACEUTICALS, INC. (NASDAQ: HEPA) (THE COMPANY OR HEPION), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY THAT HAD BEEN DEVELOPING A TREATMENT FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH), HEPATOCELLULAR CARCINOMA (HCC), AND OTHER CHRONIC LIVER DISEASES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A TERMINATION AGREEMENT WITH PHARMA TWO B LTD. WHICH TERMINATES THE MERGER AGREEMENT BETWEEN THE TWO PARTIES THAT WAS PREVIOUSLY ENTERED INTO ON JULY 19, 2024.

HEPION PHARMACEUTICALS, INC. ANNOUNCES TERMINATION OF MERGER AGREEMENT WITH PHARMA TWO B LTD.

KIRYAT ONO, ISRAEL, DEC. 05, 2024 (GLOBE NEWSWIRE) -- PHARMA TWO B , A PRIVATE, LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE COMBINATION DRUGS FOR NEUROLOGICAL DISORDERS, TODAY ANNOUNCED A POSTER PRESENTATION OF INTEGRATED SAFETY AND EFFICACY DATA ON P2B001 FROM ITS PHASE 2B AND PHASE 3STUDIES IN EARLY-STAGE PARKINSON'S DISEASE (PD) PATIENTS. P2B001 IS A FIXED, LOW-DOSE EXTENDED-RELEASE (ER) COMBINATION OF PRAMIPEXOLE, 0.6 MG AND RASAGILINE, 0.75 MG. THE DATA ARE BEING PRESENTED TODAY BY HENRY MOORE, M.D., ASSOCIATE PROFESSOR OF CLINICAL NEUROLOGY, UNIVERSITY OF MIAMI, MILLER SCHOOL OF MEDICINE, AT THE PARKINSON'S STUDY GROUP (PSG) 33 RD ANNUAL MEETING IN NASHVILLE, TN.

PHARMA TWO B ANNOUNCES POSTER PRESENTATION ON P2B001 AT THE ANNUAL MEETING OF THE PARKINSON'S DISEASE STUDY GROUP

TRANSACTION CREATES OPPORTUNITY TO SHARE IN POTENTIAL UPSIDE OF PHARMA TWO B'S LATE-CLINICAL STAGE CANDIDATE TO TREAT PARKINSON'S DISEASE

HEPION PHARMACEUTICALS ISSUES LETTER TO SHAREHOLDERS URGING SUPPORT FOR PROPOSED MERGER WITH PHARMA TWO B

KIRYAT ONO, ISRAEL AND EDISON, N.J., SEPT. 04, 2024 (GLOBE NEWSWIRE) -- PHARMA TWO B LTD. (PHARMA TWO B), A LATE-CLINICAL STAGE COMPANY THAT IS DEVELOPING P2B001, AN INNOVATIVE COMBINATION PRODUCT CANDIDATE FOR THE TREATMENT OF PARKINSON'S DISEASE (PD) AND HEPION PHARMACEUTICALS, INC. (NASDAQ: HEPA) (HEPION), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY THAT HAS BEEN DEVELOPING A TREATMENT FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH), HEPATOCELLULAR CARCINOMA (HCC), AND OTHER CHRONIC LIVER DISEASES, TODAY JOINTLY ANNOUNCED THE FILING OF A REGISTRATION STATEMENT OF PHARMA TWO B ON FORM F-4 (THE "REGISTRATION STATEMENT") WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE SEC).

PHARMA TWO B AND HEPION PHARMACEUTICALS, INC. ANNOUNCE FILING OF REGISTRATION STATEMENT ON FORM F-4 RELATED TO PROPOSED MERGER

EDISON, N.J., APRIL 19, 2024 (GLOBE NEWSWIRE) -- HEPION PHARMACEUTICALS, INC. (NASDAQ:HEPA), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY THAT HAS BEEN DEVELOPING A TREATMENT FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH), HEPATOCELLULAR CARCINOMA (HCC), AND OTHER CHRONIC LIVER DISEASES, TODAY ANNOUNCED THAT IT HAS BEGUN WIND-DOWN ACTIVITIES IN ITS ASCEND-NASH TRIAL, WHILE CONTINUING TO EXPLORE STRATEGIC ALTERNATIVES, AS PREVIOUSLY ANNOUNCED IN DECEMBER 2023.

Hepion Pharmaceuticals, Inc.

HEPA

Price

Financial Reports

No items found.

Press Releases

Hepion Pharmaceuticals, Inc.

HEPA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

HEPA